Innovations Advanced by M&A: Breakthroughs for a Rare Blood Disease

by Hanna | Jun 26, 2024 | Blog Post, Innovations Advanced by M&A

This blog is another installment in a series, Innovations Advanced by M&A, that underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. You can find previous blogs in this series here....

Innovations Advanced by M&A: An Innovative CAR-T Therapy for Blood Cancer

by Hanna | Jun 5, 2024 | Blog Post, Innovations Advanced by M&A

This blog is another installment in a series, Innovations Advanced by M&A, that underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. You can find previous blogs in this series...

Innovations Advanced by M&A: Opdivo and Yervoy’s Substantial Impact on Cancer Treatment

by Hanna | May 15, 2024 | Blog Post, Innovations Advanced by M&A

This blog is another installment in a series, Innovations Advanced by M&A, that underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. You can find previous blogs in this series here....

Innovations Advanced by M&A: The First Therapy for Pompe Disease

by Hanna | May 1, 2024 | Blog Post, Innovations Advanced by M&A

This blog is another installment in our series, Innovations Advanced by M&A, which underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. You can find previous blogs in this series...

Innovations Advanced by M&A: A Cure for Inherited Blindness

by Hanna | Apr 18, 2024 | Blog Post, Innovations Advanced by M&A

This blog is the first installment in a series, Innovations Advanced by M&A, that underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. Across the United States’ world-class life...